You play an active role in your health. Now you can advance research that may potentially protect it. Learn more about the RSVoice Trial, a clinical trial for an investigational vaccine that aims to prevent respiratory syncytial virus (RSV) infection in adults who have had an organ transplant or have preexisting health conditions.
Globally, it is estimated that RSV affects 64 million people and causes 160,000 deaths each year. 1
The purpose of this clinical trial is to assess the safety and immune response of an investigational vaccine aimed at preventing RSV infection in adults who have had an organ transplant or have preexisting health conditions. All participants in the RSVoice Trial will receive the investigational vaccine.
Who Can Join?
This clinical trial is looking for adult volunteers. To join, you must:
- Be 18 to 59 years of age and have been diagnosed with a preexisting health condition, such as:
- A cardiovascular disease—either chronic artery disease (CAD) and/or congestive heart failure (CHF)
- A chronic lung disease such as chronic obstructive pulmonary disease (COPD) or persistent asthma
- Stable type 1 or type 2 diabetes controlled with medication
- Be 18 years of age or older and have had a kidney, liver, or lung transplant
- Your organ transplant must have been at least 6 months prior, and you must be receiving chronic immunosuppressive therapy
- Not be pregnant or planning on becoming pregnant for at least 3 months following your final vaccine visit
To learn more, including how to join, contact the clinical trial site listed below.
Reference:
1. Hastie ML, Headlam MJ, Patel NB, et al. The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways. Mol Cell Proteomics. 2012;11(5):108-127. doi:10.1074/mcp.M111.015909
